VC
Value Add VC
⚡HomePulse⚡Helpful Apps📝Blog🤝Partner
Illustration for: Why Half Of 2026's IPO Class Trades Underwater
Value Add VC/Pulse/IPO~50% underwater

Why Half Of 2026's IPO Class Trades Underwater

203 companies have gone public on the NYSE or Nasdaq in 2026, but roughly half now trade below their offering price -- and Tuesday's SpaceX whipsaw shows exactly why scarcity-driven IPO pops keep failing to hold.

By the Numbers

203
2026 IPOs to date
~50%
Trading below IPO price
~$1.2T
SpaceX peak swing
TC
Trace Cohen
Early-stage VC & angel · Founder, New York Venture Partners
July 28, 2026
2 min read
ShareXLinkedInEmail

THE RUNDOWN

1

203 companies have listed on the NYSE or Nasdaq so far in 2026, the clearest reopening of the IPO window since before the 2022 rate-hike cycle froze new issuance

2

Despite that volume, roughly half of this year's IPO class now trades below its offering price -- a near coin-flip outcome that undercuts the market's celebratory narrative around IPO volume

3

SpaceX's own Tuesday whipsaw, briefly erasing $1.2 trillion in value before partially recovering, is the highest-profile live example yet of the pattern: an explosive open driven by scarcity and index-inclusion mechanics, followed by a violent reassessment once ordinary trading volume takes over

4

The pattern echoes Cerebras's May IPO (priced at $185, opened near $350, since settled into a calmer range) and suggests the market has not yet found durable clearing prices for 2026's largest, most hyped listings

TC

The VC Read · Trace's Take

Trace Cohen

A coin-flip on whether this year's entire IPO class is even above water should worry anyone treating 2026's reopening as an unambiguous win for the asset class -- volume came back, durable value creation for public shareholders clearly hasn't. SpaceX's own whipsaw this week is the pattern playing out in real time at a scale that's impossible to ignore. Founders and boards eyeing a 2026-style debut should underwrite for the grind, not the pop.

Tech IPO Tracker →

Analysis

Value Add Pulse Analysis: The 2026 IPO market has produced record volume and record volatility in roughly equal measure, and the data increasingly shows a widening gap between opening-day hype and durable public-market value creation. 203 companies have begun trading on the NYSE or Nasdaq so far this year, but roughly half now trade below their offering price -- a near coin-flip outcome that sits awkwardly next to the market's celebratory tone about the IPO window finally reopening.

SpaceX's Tuesday trading is the clearest live illustration of the mechanism driving that pattern. The stock briefly traded more than 20% below its $135 IPO price, erasing an estimated $1.2 trillion in value at the session low, before recovering some ground -- a swing that mirrors, at a far larger scale, the same scarcity-driven pop and subsequent retracement that has defined most of this year's marquee listings. Nasdaq-100 index inclusion forced an estimated $4.3 billion in passive buying against a thin 3-5% public float, manufacturing demand that had nothing to do with fundamental valuation and everything to do with mechanical index rules.

The same template shows up across this year's other headline debuts. Cerebras priced its May IPO at $185, opened near $350, and has spent the months since settling into a more sustainable range well off that early peak. Scribe Therapeutics jumped nearly 67% on its own late-July debut, a pop that will face its own test as early euphoria fades and lockups eventually expire.

“Cerebras priced its May IPO at $185, opened near $350, and has spent the months since settling into a more sustainable range well off that early peak.”

What makes 2026 different from prior IPO cycles is not the pattern itself -- explosive opens followed by long grinds toward fair value are one of the oldest lessons in public markets -- but the scale and concentration of AI-adjacent names driving it. When the single largest deal in the cohort is worth $1.77 trillion at IPO and swings by over a trillion dollars in a single session, the aggregate 'half underwater' statistic starts to look less like normal post-IPO noise and more like a market still actively searching for how to price an entirely new category of company.

For GPs and LPs evaluating exit timing over the next two quarters, the 50%-underwater figure is more decision-relevant than any single marquee debut: it says the current window rewards sellers who can exit near the opening pop far more reliably than it rewards investors holding through the settling period. Anthropic's confidential IPO filing and OpenAI's own path toward a public listing -- both first reported in early June at valuations near $965 billion and $852 billion respectively -- will be the next major tests of whether this pattern holds at even larger scale once they eventually price.

What to watch: whether the underwater percentage improves or worsens as more of this year's lockups expire through Q4, whether SpaceX stabilizes above or below its IPO price heading into its August earnings, and how underwriters adjust pricing discipline on the next wave of mega-cap listings in response to this year's volatility.

ShareXLinkedInEmail

More on

SpaceX →

Reported by Value Add Pulse Analysis · Analysis by Value Add Pulse.

← Back to Pulse

THE WIRE in your inbox— Tech, startup & VC news with Trace's take. Free, no spam.

Read Next

IPO· Aug 9, 2026

What BofA's Extreme Bull Signal Means for Your Marks

Illustration for: What BofA's Extreme Bull Signal Means for Your Marks
IPO

What BofA's Extreme Bull Signal Means for Your Marks

BofA's Bull & Bear indicator hit 9.7, its highest since 2021 and above the firm's own 8.0 sell threshold — a trace's-take on what that extreme reading should change about how GPs mark portfolio companies against public comps.

IPO· Aug 8, 2026

Biotech IPOs Are Pricing Above Range Again

Illustration for: Biotech IPOs Are Pricing Above Range Again
IPO$532.5M combined

Biotech IPOs Are Pricing Above Range Again

BlossomHill and Braveheart Bio both upsized and priced above their original ranges this week, the clearest two-deal signal yet that the biotech IPO window -- closed to all but the strongest names in 2024-2025 -- is reopening.

IPO· Aug 7, 2026

BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq

Illustration for: BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq
IPO$150M IPO

BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq

BlossomHill Therapeutics priced an upsized IPO at $16 a share for $150M and began trading on Nasdaq under BLSM, more than 50% above the $100M target Pulse flagged when the company first filed.

@Trace_Cohen·t@nyvp.com